Using skin biopsies to measure target occupancy of anti-fibrotic molecules: assay development and application for zampilimab in a primate model of chronic kidney disease and in healthy human volunteers
Zampilimab inhibited TG2 in cynomolgus monkey kidney and skin. Skin is an accessible surrogate tissue to assess kidney TO and predict TE, and our ex vivo model of skin biopsy has potential for application in the development of other antifibrotic therapeutics. A phase I first-in-human study of zampilimab in healthy volunteers (NCT02879877; 26/08/2016) will provide further proof of concept.
Authors
- Tim Schmidt
- Timothy S. Johnson (ORCID: https://orcid.org/0000-0003-3731-9632)
- Graham S. Ogg (ORCID: https://orcid.org/0000-0002-3097-045X)
- Geoffrey I. Johnston (ORCID: https://orcid.org/0000-0002-3437-4436)
- Rowann Bowcutt
- Alison Bigley
- Linghong Huang
Institutions
- University of Oxford (GB)
- Mission Therapeutics (United Kingdom) (GB)
- Oracle (United Kingdom) (GB)
- MRC Human Immunology Unit (GB)
- UCB Pharma (United Kingdom) (GB)
- Exeter Hospital (GB)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1186/s12882-025-04467-8
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00